Poxel S.A. | Key People and Executives
Thomas Kuhn
Chief Executive Officer & Director
Laurent Higueret
Director
Olivier Martinez
Director
Raphaël Wisniewski
Director
Janice Bourque
Independent Director
Pascale Boissel
Independent Director
Richard N. Kender
Independent Director
Khoso Baluch
Independent Director
Thomas Kuhn
Chief Executive Officer & Director
Anne Renevot
Chief Financial Officer
Christophe Arbet-Engels
Chief Medical Officer & EVP-Medical Affairs
Sophie Hallakou-Bozec
Senior Vice Chairman-Research & Development
Sebastien Bolze
Executive Vice President-Non Clinical Development
Pascale Fouqueray-Grellier
Executive Vice President-Translational Medicine
Noah D. Beerman
Executive Vice President-Business Development
Laurent Higueret
Director
Olivier Martinez
Director
Raphaël Wisniewski
Director
Jonae R. Barnes
Senior VP-Investor Relations & Public Relations
Janice Bourque
Independent Director
Pascale Boissel
Independent Director
Richard N. Kender
Independent Director
Mohammed Khoso Baluch
Independent Director
| Address |
259/261, avenue Jean Jaurès
Lyon Rhone-Alpes 69007
France
|
|
Employees
|
- |
| Website |
http://www.poxel.com |
| Updated |
07/08/2019 |
| Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France. |
